Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC is a phase 3, randomised interventional study registered as NCT07554846 by Fudan University, with a registry enrolment figure of 759 participants, started 2026-05-01 and due to reach its primary completion in 2030-05-01. Interventions recorded: Peroperative immunotherapy; Neoadjuvant immunotherapy; Adjuvant immunotherapy. Conditions listed: Resectable Stage II-IIIa NSCLC. Primary outcome: 3-year events-free survival (EFS) rate. Lung eligibility wording from the registry: "Subjects with resectable stage II-IIIA non-small cell lung cancer (according to the AJCC 8th edition), without EGFR/ALK sensitive mutations, confirmed by histology or pathology;". Sites: China. No results are recorded here; the registry entry is the source.